Vitamin D pathway gene variants and prostate cancer risk

50Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Vitamin D has antiproliferative, antiangiogenic, and apoptotic properties. There is some evidence supporting an association between vitamin D-related gene variants and prostate cancer risk. We report results fromthis population-based case-control study of genes encoding for the vitamin D receptor (VDR), the vitamin D activating enzyme 1-α-hydroxylase (CYP27B1), and deactivating enzyme 24-hydroxylase (CYP24A1). Forty-eight tagging single nucleotide polymorphisms (tagSNP) were analyzed in 827 incident prostate cancer cases diagnosed from2002 to 2005, and in 787 age-matched controls. Contrary to some earlier studies, we found no strong evidence of altered risk of developing prostate cancer overall or within clinical measures of tumor aggressiveness for any of the tagSNPs when they were assessed individually or in haplotypes. Copyright © 2009 American Association for Cancer Research.

Cite

CITATION STYLE

APA

Holt, S. K., Kwon, E. M., Peters, U., Ostrander, E. A., & Stanford, J. L. (2009). Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiology Biomarkers and Prevention, 18(6), 1929–1933. https://doi.org/10.1158/1055-9965.EPI-09-0113

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free